Therapeutic Cancer Vaccines - A turbulent path from bench to bedside

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-12-20

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open.


Scope

  • Research and analysis of the cancer vaccines pipeline with in-depth clinical and commercial assessment of Phase III candidates, plus expert opinion
  • Seven major pharmaceutical market sales forecasts to 2015 for key pipeline candidates incorporating product specific assumptions and events
  • Segmentation and examination of product pipeline by phase, technology platform, vaccine specificity, indication and developer
  • Insight and analysis of clinical, regulatory, pharmacoeconomic and strategic issues that challenge the path to commercialization of a cancer vaccine


    • Report Highlights
    105 different pipeline cancer vaccines have been identified of which 14 are in late-phase development. These existing candidates have a forecast sales potential of up to $3.1 billion in the seven major pharmaceutical markets by 2015.

    Despite Dendreon's Provenge preregistration status, skepticism still surrounds the use of dendritic cells as a viable technology platform. Indeed, an entirely new set of clinical and strategic issues has been brought to light across the spectrum of cancer vaccine development classes.

    While personalized immunotherapies offer greater levels of specificity and lower toxicity, generalized alternatives should facilitate production, help achieve economies of scale and offer broader utility in a range of tumor types. It is therefore not suspiring that these 'off-the-shelf' products dominate the current pipeline.


    Reasons to Purchase

  • Acquire a detailed appreciation and impartial perspective of the entire cancer vaccine developmental pipeline
  • Identify the key therapeutic cancer vaccines in late-phase development based on sales forecasts to 2015 and Datamonitor's drug assessment methodology
  • Consider, assess and react to opportunities and risks for cancer vaccines within the oncology market

    • Table of Contents

    Other users found this report page using the following search terms: cancer vaccine oncology Dendritic Cell cervical cancer melanoma trist clinical trial trovax amolimogene telovac compromise mdx1379 cost utility

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.